托尔类受体激素对人类CD8+T细胞激活和T细胞检查点受体表达的影响
Donghwan Jeon1, Jena E Moseman1, Ethan Hill1
1Department of Medicine, University of Wisconsin Carbone Cancer Center, Madison, WI, USA.
Human vaccines & immunotherapeutics
|December 18, 2025
概括
收费类受体 (TLR) 激动剂,特别是TLR3激动剂,可以增强人类CD8+T细胞的激活. 这表明TLR3激动剂可能是针对抗原特异性CD8+T细胞的癌症疫苗和免疫疗法的宝贵辅助剂.
科学领域:
- 免疫学 免疫学 免疫学
- 在T细胞激活过程中,
- 免疫治疗是一种免疫疗法.
背景情况:
- 在抗原激活时,小鼠CD8+ T细胞调高检查点受体,这一过程可能由托尔类受体 (TLR) 激动剂调节.
- 以前的研究表明,TLR激动剂可以减弱小鼠CD8+T细胞中的检查点受体表达.
研究的目的:
- 研究TLR激动剂对人类CD8+T细胞检查点受体表达和功能的影响.
- 为了确定TLR激动剂是否可以增强抗原特异性人类CD8+T细胞的激活.
主要方法:
- 人类外周血液单核细胞 (PBMCs) 与病毒特异性CD8+T细胞 (CMV或EBV) 用表位和TLR激动剂进行刺激.
- 载有病毒抗原的树突细胞 (DC) 用于在TLR3激动剂的存在下激活CD8+T细胞.
- 使用流细胞计和细胞因子分析 (IFNγ,IFNβ,IL-12) 来评估T细胞激活和受体表达.
主要成果:
- 在激活的人类CD8+T细胞上,TLR激动剂没有显著改变检查点受体表达 (PD-1,CTLA-4,LAG-3,TIGIT,TIM-3,CD160).
- 与抗原载荷DC相结合的TLR3激动剂刺激,增加了抗原特异性CD8+T细胞数量和IFNγ分泌.
- 在TLR3激动剂刺激时,DCs产生IFNβ和IL-12,与这些细胞因子的共同培养略微降低了CD8+T细胞上的CTLA-4和TIGIT表达.
结论:
- TLR3激动剂可以增强人类CD8+T细胞的激活,IFNγ产量增加证明了这一点.
- TLR3激动剂在人类抗癌疫苗和免疫疗法中显示出作为辅助剂的潜力.
- 这些发现突显了TLR3激动剂在促进抗原特异性CD8+T细胞反应方面的有用性.
相关概念视频
T Cell Activation and Clonal Selection
14.6K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
14.6K
T Cell Types and Functions
2.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.1K
Cytotoxic T Cells-mediated Immune Response
6.4K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.4K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
TGF - β Signaling Pathway
10.4K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.4K


